Expanding Bone Marrow-Derived Immune Regulatory Cells and Immune Regulatory B cells by Activating GPCR19 Pathway In vivo or In vitro

摘要

PURPOSE: Proliferation of bone marrow-derived immune regulatory cells and immune regulatory B lymphocytes in vivo and in vitro is provided to show a method for screening a therapeutic agent for treating GPCR19-related diseases or a method for analyzing efficacy of a GPCR19 agonist, thereby producing an anti-inflammatory pharmaceutical composition. CONSTITUTION: An immune regulatory B cell is transformed or proliferated by treatment with a toll-like receptor (TLR) signal transduction inducing factor and a GPCR19 agonist. The B cells show Gr-1^+CD11b^+ phenotype on the surface by treatment with the TLR signal transduction inducing factor and the GPCR19 agonist. The B cells show CD23^hi phenotype on the surface and have an anti-inflammatory activity by treatment with myeloid-derived suppressor cells (MDSC) having an anti-inflammatory activity. The B cells express CD21 and CD23. The TLR signal transduction inducing factor is lipopolysaccharide (LPS) or peptidoglycan. The GPCR19 agonist is a compound of chemical formula 1 or a salt or a hydrate thereof.